Scinai Immunotherapeutics Receives Nasdaq Notice on Minimum Bid Price Compliance

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced it received written notification from the Nasdaq Listing Qualifications Department on March 12, 2026, indicating non-compliance with the Nasdaq Capital Market's minimum bid price requirement under Listing Rule 5550(a)(2). The notification came after the company's American Depositary Shares traded below $1.00 for 30 consecutive business days, triggering the compliance notice. According to the announcement, this notice has no immediate impact on the listing or trading of the company's ADSs, allowing normal market operations to continue during the compliance period.

The company has been granted a 180-day compliance period through September 8, 2026, during which it may regain compliance if its closing bid price meets or exceeds $1.00 for at least 10 consecutive business days. This grace period provides Scinai with approximately six months to address the bid price deficiency through various corporate actions or market developments. The minimum bid price requirement is a standard Nasdaq listing maintenance rule designed to ensure listed securities maintain sufficient market value and investor interest.

Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies, advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. The company also operates Scinai Biopharma Services Ltd., a contract development and manufacturing organization providing services to biotechnology and pharmaceutical companies. The compliance issue comes as the company continues its therapeutic development programs, with the notice representing a regulatory milestone rather than an operational setback.

Investors seeking additional information about Scinai Immunotherapeutics can access the company's newsroom at https://ibn.fm/SCNI for the latest updates and announcements. The full press release detailing the Nasdaq notification is available at https://ibn.fm/faOR5, providing complete context about the compliance situation and the company's response. Nasdaq listing requirements serve as quality standards for publicly traded companies, with minimum bid price rules helping maintain market integrity and investor confidence in listed securities.

The notification process follows standard Nasdaq procedures for companies experiencing bid price deficiencies, with the 180-day compliance period representing the initial grace period available to listed companies. Should Scinai fail to regain compliance within this period, the company could potentially qualify for an additional 180-day compliance period if it meets other continued listing requirements and provides written notice of its intention to cure the deficiency. The situation highlights the ongoing regulatory requirements public companies must navigate while pursuing their business objectives in competitive markets.